Longeveron announced that Chief Financial Officer Lisa Locklear is stepping down to pursue board opportunities and other interests, with Marie Washburn appointed as Senior Vice President and CFO effective July 13. The clinical-stage biotechnology company is preparing for top-line results from its Phase 2b trial evaluating laromestrocel for Hypoplastic Left Heart Syndrome, expected in the third quarter of 2026. Washburn has served as Vice President and Corporate Controller since November 2025 and brings over 20 years of leadership experience in the pharmaceutical and biotechnology industries, having previously held senior finance roles at Fore Biotherapeutics, Axcella Health, Generation Bio, and Momenta Pharmaceuticals. Longeveron shares closed 5.94% lower at $0.6495 on the Nasdaq and fell a further 0.69% in after-hours trading to $0.6450.
Longeveron LLCCFO departure is a financial/valuation event; shares fell 5.94%.